Chronic Hepatitis C

INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.

Also Known As:

Hepatitis C, Chronic

Networked: 13936 relevant articles (1328 outcomes, 2195 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infections
2.	Virus Diseases (Viral Diseases)
3.	Fibrosis (Cirrhosis)
4.	Hepatocellular Carcinoma (Hepatoma)
5.	Hepatitis C

Experts

1.	Zeuzem, Stefan: 169 articles (01/2022 - 10/2002)
2.	Yu, Ming-Lung: 129 articles (09/2022 - 01/2002)
3.	Chuang, Wan-Long: 119 articles (09/2022 - 01/2002)
4.	Dai, Chia-Yen: 108 articles (09/2022 - 01/2002)
5.	Huang, Jee-Fu: 96 articles (09/2022 - 07/2004)
6.	Kumada, Hiromitsu: 92 articles (10/2022 - 01/2002)
7.	Chayama, Kazuaki: 85 articles (10/2022 - 01/2006)
8.	Lin, Zu-Yau: 84 articles (09/2022 - 01/2002)
9.	Sarrazin, Christoph: 84 articles (01/2022 - 12/2002)
10.	McHutchison, John G: 83 articles (07/2018 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Hepatitis C:

1.	InterferonsIBA 01/01/1994 - "We conclude that repeated interferon alpha-2b treatment courses are probably beneficial in patients with chronic hepatitis C who show a non-sustained response to interferon, since studies on the natural course of chronic hepatitis C have indicated a progressive deterioration of the histological picture in many untreated patients, most marked among those with CAH." 01/01/2017 - "Today's highly efficacious, low-toxicity interferon-free treatment regimens for chronic hepatitis C virus (HCV) can cure most patients with HCV in 12-24 weeks. " 08/01/2016 - "In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for CHC. " 04/01/2003 - "The best treatment for chronic hepatitis C patients who do not respond to interferon is still unknown. " 09/01/1998 - "Short courses (6 months) of interferon (IFN) are highly cost-effective in patients with histologically mild chronic hepatitis C. "
2.	Ribavirin (Virazole)FDA LinkGeneric 03/01/2013 - "Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis. " 07/01/2013 - "The long-term outcome, including APRI, of chronic hepatitis C patients treated successfully with PegIFN/ribavirin and followed for a mean of 5.7 years is favorable. " 07/01/2007 - "An understanding of ribavirin's beneficial effects on treatment outcome in chronic hepatitis C (CH-C) may help to develop new treatment approaches. " 03/01/2003 - "Recent data suggest that prolonging the time of treatment (12 months) may induce a significantly higher rate of sustained response among patients with genotype 1. The efficacy of the combination of IFN and ribavirin in retreating patients with chronic hepatitis C not responding to IFN monotherapy is controversial as it ranges between 0% and 40%. " 01/01/2003 - "Peginterferon-alpha-2a (40kD) plus ribavirin appears beneficial in patients with chronic hepatitis C considered difficult to treat (e.g. "
3.	Antiviral Agents (Antivirals)IBA 05/01/2023 - "The introduction of direct-acting antiviral (DAA) drugs has dramatically improved chronic hepatitis C (CHC) treatment. " 01/01/2022 - "The new generation of direct-acting antivirals has improved dramatically the rates of cure for chronic hepatitis C. " 10/01/2021 - "Direct-acting antivirals are new drugs, highly effective and safe against chronic hepatitis C. " 05/14/2021 - "The introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C, making it highly effective and safe for patients. " 01/01/2021 - "Direct-acting antivirals (DAAs) are highly effective in treating chronic hepatitis C virus (HCV)-infected patients. "
4.	Interferon-alpha (Interferon Alfa)IBA 04/01/1996 - "Some patients with chronic hepatitis C are very sensitive to alpha interferon and can be successfully treated with low doses. " 02/01/1996 - "Alpha interferon (IFN-alpha) is, to date, the only treatment with proven efficacy in patients with chronic hepatitis C. " 02/01/1993 - "Interferon-alpha (IFN-alpha) has proven useful in the treatment of chronic hepatitis C, but a relapse in response is frequently observed. " 05/01/1999 - "Prediction of successful outcome in a randomised controlled trial of the long-term efficacy of interferon alpha treatment for chronic hepatitis C." 10/01/2010 - "Large numbers of patients suffering from Chronic Hepatitis C (HCV) are seeking treatment with interferon alpha (IFN) because of significant advances in overall improvement in the course of HCV and its complications. "
5.	RNA (Ribonucleic Acid)IBA 03/28/2010 - "Short-term PEG-IFN alpha2a monotherapy is highly effective for chronic hepatitis C patients who have low pretreatment HCV RNA load and exhibit IVR." 09/01/2001 - "One approach (study 1) was to compare the efficacy of a 6 month course of three different dosages of recombinant IFN-alpha-2a in patients with chronic hepatitis C associated with HCV-genotype 1b and a high serum HCV-RNA level of more than 1 Meq/ml. Another approach (study 2) was to make clear the significance of an additional 6 month course of IFN in patients who had biochemical response during the first 6 month course of IFN (study 1). " 09/01/2007 - "There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA. " 01/01/2006 - "Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load." 07/01/2005 - "RIB administration preceding combined treatment of RIB with IFN was more effective in Th2 cell expansion than the usual combined treatment of IFN with RIB and led to a relatively early virological clearance in chronic hepatitis C patients with genotype 1b and a high HCV RNA level."
6.	SofosbuvirIBA 01/01/2018 - "The combination of sofosbuvir (SOF) plus an NS5A inhibitor for 12 weeks is highly efficacious in patients with chronic hepatitis C. " 01/01/2021 - "Sofosbuvir based regimens were effective and safe in the treatment of cirrhotic patients with chronic hepatitis C genotype 4." 02/01/2023 - "The efficacy of sofosbuvir (SOF)-based regimens in the treatment of chronic hepatitis C (HCV) patients with and without human immunodeficiency virus (HIV) co-infected patients in real-world setting is limited. " 03/01/2017 - "Sofosbuvir-based regimens have improved treatment success in chronic hepatitis C. " 01/01/2022 - "We recruited sofosbuvir-treated patients with chronic hepatitis C from five Canadian treatment sites, and performed a case-control pharmacogenomics study assessing both previously published and novel genetic polymorphisms. "
7.	telaprevirIBA 07/01/2013 - "Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study." 03/26/2012 - "In in vitro studies, telaprevir shows good activity against genotype 1 HCV, including viral isolates from patients with chronic hepatitis C. " 03/01/2012 - "The examination of HCV virological clearance through several randomized clinical trials of telaprevir in genotype 1 chronic hepatitis C. " 05/01/2011 - "Clinical studies were identified through MEDLINE (1966-January 2011), bibliographies of articles, clinicaltrials.gov, and fda.gov, using key words VX-950, telaprevir, and chronic hepatitis C. " 02/01/2011 - "Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients."
8.	Interferon alpha-2 (Roferon-A)FDA Link 01/01/1997 - "[The therapeutic efficacy of interferon-alfa-2a (Roferon-A) in chronic hepatitis C]." 02/01/1995 - "[A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C]." 03/01/1999 - "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients." 10/01/1998 - "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients." 01/01/1993 - "Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C."
9.	Amantadine (Aman)FDA LinkGeneric 04/01/1999 - "However, few studies about efficacy of amantadine in chronic hepatitis C are available with controversial results. " 11/01/2001 - "Efficacy of amantadine hydrochloride in patients with chronic hepatitis C." 01/01/2000 - "We aimed to test the efficacy of amantadine in chronic hepatitis C (CHC) patients infected with genotype b. " 05/03/2014 - "Based on the results of the overall evidence, it appears less likely that future trials assessing amantadine for patients with chronic hepatitis C will show strong benefits. " 10/01/2010 - "Aim of our study was to investigate whether amantadine alters IFN associated down regulation of CD81 expression on PBMC in patients with chronic hepatitis C. "
10.	sofosbuvir drug combination ledipasvirIBA 01/01/2022 - "The sofosbuvir/ledipasvir combination is effective in treating genotype 1b chronic hepatitis C with high sustained virologic response rates. " 01/01/2021 - "Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study." 01/01/2022 - "Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting." 01/01/2020 - "Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study." 01/01/2020 - "Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years."

Therapies and Procedures

1.	Therapeutics 11/01/2007 - "The treatment of chronic hepatitis C has become a priority in hepatitis C virus/HIV-coinfected patients, and the best results are obtained by tailoring therapy to the individual patient's characteristics." 10/01/2007 - "Therapy for chronic hepatitis C has improved dramatically over the past 20 years. " 01/01/2002 - "Using this model, it was shown that (1) IFN therapy for chronic hepatitis C (CHC) would be economically beneficial at least in the Japanese situation, (2) the complete response rate to therapy would be the most sensitive factor affecting outcome, and (3) the younger the person cured by IFN therapy, the greater the benefit seen. " 03/01/2020 - "Direct-acting anti-virals (DAAs) have markedly improved the effectiveness of anti-viral therapy for chronic hepatitis C (CHC) patients. " 01/01/2015 - "Optimal therapy in genotype 4 chronic hepatitis C: finally cured?"
2.	Retreatment 12/01/2003 - "OBJECTIVES: To investigate the efficacy of prolonged IFN retreatment for 3 years in chronic hepatitis C patients with high viral load and IFN treatment-resistant genotype 1b. " 05/01/1997 - "In conclusion, this combination treatment was more effective than retreatment with IFN-alpha, alone, in inducing sustained biochemical remission of chronic hepatitis C that was resistant to a previous course of IFN-alpha. " 08/01/2018 - "The present case report indicated a case in which GZR/EBR was effective for the retreatment of a patient with a history of failed LDV/SOF treatment and chronic hepatitis C. " 10/01/2019 - "This study establishes the efficacy of GLE/PIB as retreatment in Japanese patients with GT2 chronic hepatitis C not responding to SOF + RBV." 11/01/1997 - "The aim of this study was to define the efficacy of IFN retreatment in chronic hepatitis C. "
3.	Renal Dialysis (Hemodialysis) 01/01/2011 - "Liver biopsy is an imperfect gold standard for assessing the disease severity in hemodialysis patients with chronic hepatitis C. " 08/01/2015 - "The aim of the study was to evaluate the association between SNPs near the IL28B gene and response to the treatment of chronic hepatitis C in hemodialysis patients. " 01/01/2009 - "At the end of the study, peg-IFN-alpha-2a treatment of patients with chronic hepatitis C on maintenance hemodialysis may improve prognosis and their quality of life." 11/01/2001 - "Eleven hemodialysis patients with chronic hepatitis C that received IFNalpha treatment were included in this study. " 11/01/2001 - "The aim of this study was to evaluate serum beta2-microglobulin levels in 11 hemodialysis patients with chronic hepatitis C treated with IFNalpha. "
4.	Liver Transplantation 01/01/2018 - "Excellent efficacy and safety profile of second-generation DAA combinations improved treatment of chronic hepatitis C (HCV) as well as in HCV recurrence after orthotopic liver transplantation (OLT). " 04/01/2009 - "In conclusion, posttransplant survival after orthotopic liver transplantation for chronic hepatitis C has improved significantly over the last 15 years despite demographic changes in patients and grafts that have been previously shown to impair survival. " 02/27/2022 - "We report three cases of spontaneous resolution of chronic hepatitis C following liver transplantation. " 02/27/2022 - "Learning from a rare phenomenon - spontaneous clearance of chronic hepatitis C virus post-liver transplant: A case report." 08/01/2008 - "Spontaneous clearance of chronic hepatitis C after liver transplantation: are hepatitis C virus-specific T cell responses the clue?"
5.	Aftercare (After-Treatment) 04/01/2011 - "The efficacy of treatment in chronic hepatitis C is defined as absence of detectable virus at six months after treatment. " 03/01/2011 - "Delayed viral clearance of chronic hepatitis C in patients after treatment failure." 01/01/2011 - "The aim of this study was to use TE to evaluate whether patients with sustained virological response (SVR) have lower liver stiffness than patients with non-SVR after treatment for chronic hepatitis C (CHC). " 01/01/2005 - "In this study, sCD30 serum levels in 25 patients with chronic hepatitis C, before and after treatment with IFN-2alpha, were measured. " 12/01/1998 - "In order to discuss the anti-viral effects of IFN alpha-2a and IFN alpha-2b on chronic hepatitis C in a short and long period of time after treatment, 70 cases of chronic hepatitis C treated with IFN alpha-2a, 46 cases with IFN alpha-2b and 28 cases as controls had been investigated in this study. "